跳转至内容
Merck
CN
  • Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.

Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.

European journal of clinical pharmacology (2014-06-24)
Kyra J Barnes, Andrew Rowland, Thomas M Polasek, John O Miners
摘要

To investigate the potential inhibitory effects of uremic toxins on the major human hepatic drug-metabolising cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes in vitro. Benzyl alcohol, p-cresol, indoxyl sulfate, hippuric acid and a combination of the four uremic toxins were co-incubated with human liver microsomes and selective probe substrates for the major human drug-metabolising CYP and UGT enzymes. The percentage of enzyme inhibition was calculated by measuring the rates of probe metabolite formation in the absence and presence of the uremic toxins. Kinetics studies were conducted to evaluate the K i values and mechanism(s) of the inhibition of CYP2E1, CYP3A4, UGT1A1 and UGT1A9 by p-cresol. The individual uremic toxins inhibited CYP and UGT enzymes to a variable extent. p-Cresol was the most potent individual inhibitor, producing >50% inhibition of CYP2E1, CYP3A4, UGT1A1, UGT1A9 and UGT2B7 at a concentration of 100 μM. The greatest inhibition was observed with UGT1A9. p-Cresol was shown to be an uncompetitive inhibitor of UGT1A9, with unbound K i values of 9.1 and 2.5 μM in the absence and presence of bovine serum albumin (BSA), respectively. K i values for p-cresol inhibition of human liver microsomal CYP2E1, CYP3A4 and UGT1A1 ranged from 43 to 89 μM. A combination of the four uremic toxins produced >50% decreases in the activities of CYP1A2, CYP2C9, CYP2E1, CYP3A4, UGT1A1, UGT1A9 and UGT2B7. Uremic toxins may contribute to decreases in drug hepatic clearance in individuals with kidney disease by inhibition of hepatic drug-metabolising enzymes.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
苯甲醇, ReagentPlus®, ≥99%
Sigma-Aldrich
苯甲醇, ACS reagent, ≥99.0%
Supelco
苯甲醇, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
对乙酰氨基酚, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
4-硝基苯酚, ReagentPlus®, ≥99%
USP
苯甲醇, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
对甲酚, 99%
Sigma-Aldrich
苯甲醇, puriss., meets analytical specification of Ph. Eur., BP, NF, 99-100.5% (GC)
USP
对乙酰氨基酚, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
氟康唑, ≥98% (HPLC), powder
Sigma-Aldrich
对乙酰氨基酚, BioXtra, ≥99.0%
Sigma-Aldrich
β-磷酸烟酰胺腺嘌呤二核苷酸 水合物
Sigma-Aldrich
苯甲醇, anhydrous, 99.8%
Sigma-Aldrich
非那西丁, ≥98.0% (HPLC)
Sigma-Aldrich
对乙酰氨基酚, meets USP testing specifications, 98.0-102.0%, powder
Sigma-Aldrich
苯甲醇, puriss. p.a., ACS reagent, ≥99.0% (GC)
Sigma-Aldrich
对乙酰氨基酚, analytical standard
Sigma-Aldrich
马尿酸, 98%
Sigma-Aldrich
4-硝基苯酚 溶液, 10 mM
Supelco
睾酮 溶液, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
氟康唑, Pharmaceutical Secondary Standard; Certified Reference Material
扑热息痛, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
苯甲醇, ≥99%, FCC, FG
Sigma-Aldrich
对甲酚, ≥99%, FG
Sigma-Aldrich
酮康唑, 99.0-101.0% (EP, titration), meets EP testing specifications
Sigma-Aldrich
奎宁, suitable for fluorescence, anhydrous, ≥98.0% (dried material, NT)
Supelco
苯甲醇, analytical standard
Supelco
酮康唑, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
普鲁泊福, 97%
Sigma-Aldrich
4-硝基苯酚, spectrophotometric grade